AI Healthcare Regulations in Missouri: A Comprehensive Guide

Quick Answer: Current State of AI Healthcare Regulation in Missouri

Missouri has not enacted a comprehensive, AI-specific healthcare statute. For providers deploying a diagnostic algorithm or developers selling a clinical decision support tool to a Missouri hospital, primary compliance obligations stem from three sources: federal FDA oversight of software and medical devices, federal HIPAA privacy and security rules, and Missouri's general healthcare statutes covering physician practice, patient consent, and data breach notification.

This creates a regulatory patchwork with potential liability gaps. The Missouri Department of Health and Senior Services (DHSS) and the Missouri Board of Registration for the Healing Arts have not issued AI-specific guidance as of mid-2025. Providers and developers must extrapolate from existing rules. While several states have moved toward AI-specific legislation, Missouri has not passed such a bill through the General Assembly as of this writing. Monitor the Missouri Legislature's bill tracking system (house.mo.gov and senate.mo.gov) for emerging proposals each session.

Practically speaking, if an AI tool meets the FDA's definition of a medical device or Software as a Medical Device (SaMD), federal premarket review applies regardless of where it is used. If it handles protected health information (PHI), HIPAA applies. Missouri law then adds a second layer concerning professional accountability, patient consent, and breach notification.

Federal Framework: FDA's Role in AI Medical Devices and Software

The FDA is the dominant regulator for AI tools that diagnose, treat, or monitor patients. Missouri providers cannot opt out of this framework by citing state law.

Software as a Medical Device (SaMD)

The FDA classifies AI and machine learning (ML) tools meeting the medical device definition under 21 U.S.C. §321(h) as Software as a Medical Device. The agency's "Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan" (FDA, January 2021) established a five-part framework. This framework covers good machine learning practices, transparency, real-world performance monitoring, regulatory science, and a predetermined change control plan for adaptive algorithms. This action plan remains the foundational policy for FDA's approach to adaptive AI tools.

Premarket Review Pathways

The pathway an AI product must follow depends on its risk classification:

Most currently authorized AI/ML devices have cleared through 510(k) or De Novo. A cross-sectional analysis of FDA-authorized oncology AI/ML devices found that the majority of cleared tools in cancer care relied on imaging data and used 510(k) clearance. However, clinical evidence quality varied considerably across products (Litt H et al., Journal of Cancer Policy, 2026, PMID 42025919). This finding is relevant for Missouri oncology practices: FDA clearance does not automatically mean the underlying clinical evidence is robust. Procurement decisions should include independent review of supporting studies.

Clinical Decision Support Software

Not all AI tools are regulated as devices. The FDA's final guidance "Clinical Decision Support Software" (September 2022) distinguishes between software that is a device (and therefore regulated) and non-device CDS that falls outside FDA jurisdiction. Key factors include whether the software acquires, processes, or analyzes medical images or signals. It also considers whether the software is intended to replace clinical judgment and whether a clinician can independently review the basis for a recommendation. If a tool displays its reasoning and a qualified clinician can verify it without relying solely on the software's output, it is